Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Lineage Cell Therapeutics Inc (AMEX: LCTX) closed at $1.15 down -4.17% from its previous closing price of $1.20. In other words, the price has decreased by -$4.17 from its previous closing price. On the day, 1.1 million shares were traded. LCTX stock price reached its highest trading level at $1.23 during the session, while it also had its lowest trading level at $1.12.
Ratios:
For a deeper understanding of Lineage Cell Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.14 and its Current Ratio is at 2.14. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on November 02, 2022, initiated with a Outperform rating and assigned the stock a target price of $5.
On June 14, 2022, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.
On August 19, 2021, Noble Capital Markets started tracking the stock assigning a Outperform rating and target price of $8.Noble Capital Markets initiated its Outperform rating on August 19, 2021, with a $8 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 08 ’24 when BAILEY DON M bought 96,155 shares for $1.04 per share. The transaction valued at 100,001 led to the insider holds 158,801 shares of the business.
BROADWOOD PARTNERS, L.P. bought 6,730,770 shares of LCTX for $7,000,001 on Feb 06 ’24. The Director now owns 41,666,255 shares after completing the transaction at $1.04 per share. On Dec 29 ’23, another insider, Jayasuriya Anula, who serves as the Director of the company, bought 10,000 shares for $1.09 each. As a result, the insider paid 10,900 and bolstered with 10,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LCTX now has a Market Capitalization of 216814096 and an Enterprise Value of 182877568. For the stock, the TTM Price-to-Sale (P/S) ratio is 24.22 while its Price-to-Book (P/B) ratio in mrq is 3.17. Its current Enterprise Value per Revenue stands at 20.445 whereas that against EBITDA is -8.916.
Stock Price History:
Over the past 52 weeks, LCTX has reached a high of $1.61, while it has fallen to a 52-week low of $0.84. The 50-Day Moving Average of the stock is -5.30%, while the 200-Day Moving Average is calculated to be -4.70%.
Shares Statistics:
For the past three months, LCTX has traded an average of 970.83K shares per day and 999690 over the past ten days. A total of 188.53M shares are outstanding, with a floating share count of 187.49M. Insiders hold about 0.55% of the company’s shares, while institutions hold 48.05% stake in the company. Shares short for LCTX as of 1711584000 were 10397492 with a Short Ratio of 10.71, compared to 1709164800 on 9623107. Therefore, it implies a Short% of Shares Outstanding of 10397492 and a Short% of Float of 7.430000000000001.
Earnings Estimates
The current market rating for Lineage Cell Therapeutics Inc (LCTX) reflects the collective analysis of LCTU analysts closely monitoring its performance.The consensus estimate for the next quarter is $46.57, with high estimates of $2.01 and low estimates of $1.15.
